ARQT Q3 2023 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38M+5156.4% YoY

Gross Profit

$37M96.9% margin

Operating Income

-$37M-96.8% margin

Net Income

-$45M-117.5% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

+634.3%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$44M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$293M

Total Liabilities

$246M

Stockholders' Equity

$47M

Cash & Equivalents

$107M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$725,000	+5156.4%
Gross Profit	$37M	$456,000	+7998.0%
Operating Income	-$37M	-$105M	+64.8%
Net Income	-$45M	-$108M	+58.4%

Revenue Segments

Other Revenue

$30M79%

Product

$8M21%